MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients

Why did Tesla’s stock plunge amid Musk-Trump feud? How will US-China trade talks impact tariffs? What caused the slowdown in US job growth? Why is Lululemon’s stock crashing today? How did Musk’s feud with Trump affect SpaceX? What’s behind the renewed US oil price rise? Why is United Airlines ending Starlink on jets?

MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients

benzinga.com/markets/biotech/25/06/45800623/maia-biotechnologys-experimental-cancer-drug-shows-tripled-survival-vs-standard-chemotherapy-in-p

MAIA Biotechnology, Inc. (NASDAQ:MAIA) on Thursday revealed updated data from its THIO-101 pivotal Phase 2 clinical trial.
The trial is evaluating its lead clinical candidate, ateganosine (THIO), sequenced with Regeneron Pharmaceutical Inc’s (NASDAQ:REGN) immune checkpoint inhibitor (CPI)…

This story appeared on benzinga.com, 2025-06-05 18:28:49.